ROCKY HILL, Conn. (PRWEB)
June 25, 2020
Lumeda Inc. (“Lumeda”), a biophotonics systems company formed to advance photodynamic therapy for treating cancer, today announced the company has entered a license agreement with Roswell Park Comprehensive Cancer Center of Buffalo, New York (“Roswell Park”). The agreement provides Lumeda globally exclusive rights to Roswell Park intellectual property surrounding a novel medical device and method for intraoperative photodynamic therapy (IO-PDT), which can be used for treating non-small cell lung cancer (NSCLC).
PDT is an established treatment for a range of cancers but, despite its promise in NSCLC, its broad adoption is hindered by its current treatment delivery mode that is difficult to perform with inconsistent results. The Roswell Park innovation enables a simplified and more effective IO-PDT procedure that could be added to the Standard of Care in NSCLC tumor resection.
“Entering this agreement marks the start of refinement and ultimate introduction of this important lung cancer therapy to the clinic,” according to Trevor MacDougall, one of the founders of Lumeda. “This agreement fosters further collaboration between the world’s leading PDT center and Lumeda’s proven photonics product development team.”
Under the agreement, Lumeda will apply its photonics design and development capabilities to commercialize a complete automated IO-PDT solution.
Photodynamic therapy (PDT) was developed at Roswell Park, which remains a worldwide leader in PDT research and clinical application as a treatment for many types of cancer.
About Roswell Park Comprehensive Cancer Center:
Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at http://www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@RoswellPark.org.
Lumeda is advancing PDT to treat NSCLC and other thoracic malignancies. The company applies advanced photonics and proprietary software to automate and digitize PDT light delivery to improve PDT efficacy, ease of use, and treatment planning. The multidisciplinary Lumeda team has decades of experience in the photonics industry, with significant expertise and strength in systems engineering, factory operations, and the commercialization of new products and technology. Lumeda is committed to pioneering the advancement and utility of PDT for improved patient outcomes. For more information, please visit http://www.lumedainc.com.
Share article on social media or email: